(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 42.37% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.59%.
Eton Pharmaceuticals's revenue in 2026 is $105,595,000.On average, 6 Wall Street analysts forecast ETON's revenue for 2026 to be $4,164,562,770, with the lowest ETON revenue forecast at $3,364,520,821, and the highest ETON revenue forecast at $4,571,014,949. On average, 6 Wall Street analysts forecast ETON's revenue for 2027 to be $6,425,202,917, with the lowest ETON revenue forecast at $5,688,615,528, and the highest ETON revenue forecast at $7,102,051,553.
In 2028, ETON is forecast to generate $8,715,569,524 in revenue, with the lowest revenue forecast at $7,809,769,976 and the highest revenue forecast at $10,670,941,790.